Pivotal Therapeutics Announces Notice of Allowance for U.S. Patent on its Unique 6:1 EPA:DHA Formulation

Woodbridge, Ontario (ots/PRNewswire) -

Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty
pharmaceutical company with a focus on Omega-3 therapies, announced
that it received a Notice of Allowance for U.S. Application Serial
Number US2012/025014 from the United States Patent and Trademark
Office (USPTO). The patent titled "Formulations Comprising Omega-3
Fatty Acids and Anti-Obesity Agent for the Reduction of Body Weight
in Cardiovascular Disease Patients (CVD) and Diabetics" covers
Pivotal's unique formulation in conjunction with anti-obesity agents
for the reduction of body weight in CVD patients and diabetics. This
notice constitutes allowance of the patent and impending issuance.

"This Notice of Allowance is an important step in the process of
broadening our intellectual property portfolio, further validates our
unique 6:1 EPA:DHA formulation and when used in combination with
anti-obesity drugs may play a positive role in obesity," said Dr.
George Jackowski, Chairman and Chief Scientific Officer. "Obesity and
diabetes are large markets, and this allowed patent may open the
doors to potential partnerships with pharmaceutical companies that
are currently working on treatments in these areas," added Dr.
Jackowski.

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CNSX:
PVO) specialty pharmaceutical company with a focus on cardiovascular
disease and overall health. Pivotal Therapeutics' lead product
VASCAZEN(R) is a prescription only Medical Food formulated to meet
the dietary Omega-3 deficient needs of patients with cardiovascular
disease through elevating Eicosapentaenoic acid (EPA) and
Docosahexaenoic acid (DHA) to levels associated with reduced risk of
cardiovascular complications. OMAZEN(R)is a pharmaceutical grade
Omega-3 providing over 90% pure Omega-3 in each capsule for the
maintenance of good health. OMAZEN(R) is a patented product available
for sale and distribution in Canada.

About VASCAZEN(R)

VASCAZEN(R) is currently available in the U.S. as a
prescription-only Medical Food specifically formulated for the
dietary management of an Omega-3 deficiency in cardiovascular
patients. VASCAZEN(R) is a >90% pure Omega-3 with a proprietary 6:1
EPA:DHA fatty acid formulation, protected by a series of both U.S.
and foreign patents.

VASCAZEN(R) has been clinically shown to correct an Omega-3
deficiency within eight weeks of treatment with positive concomitant
effects on the lipid profiles, mainly a 48% reduction of
triglycerides and an increase of HDL without negative impact on the
LDL-C lipid profile. VASCAZEN(R)'s results were achieved with a dose
of 3 grams of EPA and DHA per day of a prescription grade, high
purity Omega-3.

Disclosure Notice

The information contained in this document is as of January 29,
2014. This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual
results to differ materially from those projected in such
forward-looking statements. These statements can be identified by the
use of words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe", "project",
"potential", and similar expressions with any discussion of future
operating or financial performance or events. In particular, factors
that could cause actual results to differ materially from those in
forward looking statements include the following: Pivotal's inability
to obtain additional financing on acceptable terms; growth in costs
and expenses; inability to compete with others who provide comparable
products; risk that the Company's products will not gain widespread
market acceptance; risks relating to the Company's ability to
maintain its CSNX listing. Forward-looking statements speak only as
of the date made and are not guarantees of future performance. The
Company undertakes no obligation to publicly update or revise any
forward-looking statements contained in this document as a result of
new information or future events or developments. CNSX has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this information.

Company Contacts:

Rachelle MacSweeney
President and Chief Operating Officer
Phone: +1-905-856-9797
E-Mail: rmacsweeney@pivotaltherapeutics.us

Kristine DiMatteo
Communications and Public Relations Manager
Phone: +1-905-856-9797 ext. 231
E-Mail: kdimatteo@pivotaltherapeutics.us

http://www.pivotaltherapeutics.us

ots Originaltext: Pivotal Therapeutics Inc
Im Internet recherchierbar: http://www.presseportal.de